Hannah E. Maier

Hannah E. Maier


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
HMHannah E. Maier
Hannah E. Maier
RNRaffael Nachbagauer
Raffael Nachbagauer
GKGuillermina Kuan
Guillermina Kuan
SNSophia Ng
Sophia Ng
RLRoger Lopez
Roger Lopez
AGAubree Gordon
Aubree Gordon
Background: Influenza causes a substantial burden worldwide, and current seasonal influenza vaccine has suboptimal effectiveness. To develop better, more broadly protective vaccines, a more thorough understanding is needed of how antibodies that target the influenza virus surface antigens, hemagglutinin (HA) (including head and stalk regions) and neuraminidase (NA), impact influenza illness and virus transmission. Methods: We used a case-ascertained, community-based study of household influenza virus transmission set in Managua, Nicaragua. Using data from 170 reverse transcriptase–polymerase chain reaction (RT-PCR)–confirmed influenza virus A(H1N1)pdm infections and 45 household members with serologically confirmed infection, we examined the association of pre-existing NA, hemagglutination inhibiting, and HA stalk antibody levels and influenza viral shedding and disease duration using accelerated failure time models. Results: Among RT-PCR–confirmed infections in adults, pre-existing anti-NA antibody levels ≥40 were associated with a 69% (95% confidence interval [CI], 34–85%) shortened shedding duration (mean, 1.0 vs 3.2 days). Neuraminidase antibody levels ≥80 were associated with further shortened shedding and significantly shortened symptom duration (influenza-like illness, 82%; 95% CI, 39–95%). Among RT-PCR–confirmed infections in children, hemagglutination inhibition titers ≥1:20 were associated with a 32% (95% CI, 13–47%) shortened shedding duration (mean, 3.9 vs 6.0 days). Conclusions: Our results suggest that anti-NA antibodies play a large role in reducing influenza illness duration in adults and may impact transmission, most clearly among adults. Neuraminidase should be considered as an additional target in next-generation influenza virus vaccine development. We found that antibodies against neuraminidase were associated with significantly shortened viral shedding, and among adults they were also associated with shortened symptom duration. These results support neuraminidase as a potential target of next-generation influenza virus vaccines.

23 January 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
HMHannah E. Maier
Hannah E. Maier
TKTheresa Kowalski-Dobson
Theresa Kowalski-Dobson
AEAshley Eckard
Ashley Eckard
CGCarmen Gherasim
Carmen Gherasim
DMDavid Manthei
David Manthei
AGAubree Gordon
Aubree Gordon
The impact of vaccination prior to infection on postacute sequelae of coronavirus disease 2019 (COVID-19, PASC), also known as long COVID, remains unclear. Here we assess the protective effect of vaccination on long COVID in a community-based setting. The Immunity Associated with SARS-CoV-2 (IASO) study is an ongoing prospective cohort of working adults that began in October 2020. Participants are actively followed for severe acute respiratory syndrome coronavirus 2 infection. We compared the prevalence of symptoms and symptom severity in vaccinated compared to unvaccinated cases. Our primary definition of long COVID was the presence of symptoms at 90 days postinfection; 30 days postinfection was also examined. Overall, by 90 days postinfection, 13% of cases had long COVID, with 27% of unvaccinated cases and 8% of vaccinated cases reporting long COVID (relative risk [RR], 0.31 [95% confidence interval {CI}, .22–.42]). Vaccination was also associated with significantly lower average severity scores at all timepoints (eg, relative severity at 90 days postinfection: −2.70 [95% CI, −1.68 to −3.73]). In the pre-Omicron era, 28% of unvaccinated cases and 18% of vaccinated cases reported long COVID (P = .07), and vaccinated cases reported less severe symptoms including less difficulty breathing (P = .01; 90-day RR, 0.07). Vaccinated cases had lower prevalence of long COVID and reduced symptom severity.

20 July 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
HMHannah E. Maier
Hannah E. Maier
ABAngel Balmaseda
Angel Balmaseda
SSSaira Saborio
Saira Saborio
SOSergio Ojeda
Sergio Ojeda
CBCarlos Barilla
Carlos Barilla
AGAubree Gordon
Aubree Gordon
The course of the current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will be determined in part by the quality and durability of protective immunity induced by previous infection, vaccination, or both, as well as by the severity of illness in persons with some level of immunity.1,2 From March 2020 through October 2021 in the Household Influenza Cohort Study (HICS) study, we followed 2353 participants, ranging in age from newborn infants to elderly persons up to 94 years of age, in 437 households in Nicaragua for the presence of SARS-CoV-2 infection ( Figure 1A ). The study was approved by the institutional review boards at the Nicaraguan Ministry of Health, the University of Michigan, and the University of California, Berkeley. All the participants (or their parents or guardians if they were under the age of 18 years) provided written informed consent; children who were 6 years of age or older also provided assent.

24 November 2021 in medRxiv
Verified
Preprint
Open access
PDF file
HMHannah E. Maier
Hannah E. Maier
ABAngel Balmaseda
Angel Balmaseda
SOSergio Ojeda
Sergio Ojeda
CCCristiam Cerpas
Cristiam Cerpas
NSNery Sanchez
Nery Sanchez
AGAubree Gordon
Aubree Gordon
Background An immune correlate of protection from SARS-CoV-2 infection is urgently needed. Methods We used an ongoing household cohort with an embedded transmission study that closely monitors participants regardless of symptom status. Real-time reverse-transcription polymerase chain reaction (RT-PCR) and Enzyme-linked immunosorbent assays (ELISAs) were used to measure infections and seropositivity. Sequencing was performed to determine circulating strains of SARS-CoV-2. We investigated the protection associated with seropositivity resulting from prior infection, the anti-spike antibody titers needed for protection, and we compared the severity of first and second infections. Results In March 2021, 62.3% of the cohort was seropositive. After March 2021, gamma and delta variants predominated. Seropositivity was associated with 69.2% protection from any infection (95% CI: 60.7%-75.9%), with higher protection against moderate or severe infection (79.4%, 95% CI: 64.9%-87.9%). Anti-spike titers of 327 and 2,551 were associated with 50% and 80% protection from any infection; titers of 284 and 656 were sufficient for protection against moderate or severe disease. Second infections were less severe than first infections (Relative Risk (RR) of moderated or severe disease: 0.6, 95% CI: 0.38-0.98; RR of subclinical disease:1.9, 95% CI: 1.33-2.73). Conclusions Prior infection-induced immunity is protective against infection when predominantly gamma and delta SARS-CoV-2 circulated. The protective antibody titers presented may be useful for vaccine policy and control measures. While second infections were somewhat less severe, they were not as mild as ideal. A strategy involving vaccination will be needed to ease the burden of the SARS-CoV-2 pandemic.

11 December 2025 in Nature Communications
Verified
Journal Article
Open access
GHGregory Hoy
Gregory Hoy
TCThomas Cortier
Thomas Cortier
HMHannah E. Maier
Hannah E. Maier
GKGuillermina Kuan
Guillermina Kuan
RLRoger Lopez
Roger Lopez
AGAubree Gordon
Aubree Gordon
Immune responses against neuraminidase (NA) and hemagglutinin (HA) are critical for developing effective influenza vaccines, yet their role in influenza transmission remains unclear. We conducted household transmission studies in Managua, Nicaragua, to assess the impact of anti-NA and anti-HA antibodies induced by natural infection on influenza A/H3N2 susceptibility and infectivity. Using mathematical models capturing household transmission dynamics, we found that high pre-existing antibody levels against the HA head (>31, [95% CrI 13–67]), HA stalk (>35, [95% CrI 11–66]), and NA (>31, [95% CrI 12–68]) are associated with reduced susceptibility to infection (relative susceptibility: HA head, 0.63 [95% CrI 0.42–0.98]; HA stalk, 0.66 [95% CrI 0.44–0.99]; NA, 0.49 [95% CrI 0.30–0.76]). HA stalk (>58 [95% CrI: 47–70]) and NA (>27 [95% CrI: 15–43]) are associated with reduced infectivity (relative infectivity: NA, 0.55 [95% CrI: 0.32–0.98], HA stalk 0.53 [95% CrI: 0.27–0.97]). These findings suggest that influenza vaccines designed to elicit NA immunity in addition to HA immunity may not only enhance protection against infection but also reduce onward transmission.

19 March 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
JZJose Victor Zambrana
Jose Victor Zambrana
CSCarlos Saenz
Carlos Saenz
HMHannah E. Maier
Hannah E. Maier
MBMayling Brenes
Mayling Brenes
ANAndrea Nuñez
Andrea Nuñez
ABAngel Balmaseda
Angel Balmaseda
Few data are available on antibody response for some SARS-CoV-2 vaccines, and there is a lack of ability to compare vaccine responses in the same population. This cross-sectional study conducted in Nicaragua examines the SARS-CoV-2 antibody responses in individuals, previously exposed to high infection rates who have received various vaccines. The vaccines under comparison include well-known ones like Pfizer (BNT162b2) and AstraZeneca (ChAdOx1-S), alongside less-studied vaccines including Soberana (Soberana 02), Abdala (CIGB-66), and Sputnik V/Sputnik Light. Overall, 3195 individuals participated, with 2862 vaccinated and 333 unvaccinated. We found that 95% of the unvaccinated were seropositive, with much lower titers than the vaccinated. Among the vaccinated, we found that Soberana recipients mounted the highest anti-spike response (mean difference (MD) = 36,498.8 [20,312.2, 52,685.5]), followed by Abdala (MD = 25,889.9 [10,884.1, 40,895.7]), BNT162b2 (MD = 12,967.2 [7543.7, 18,390.8]) and Sputnik with AstraZeneca as the reference group, adjusting for age, sex, vaccine status, days after last dose, and self-reported COVID-19. In addition, we found that subjects with complete vaccination series had higher antibody magnitude than those with incomplete series. Overall, we found no evidence of waning in the antibody magnitude across vaccines. Our study supports the conclusion that populations with high infection rates still benefit substantially from vaccination.